<DOC>
	<DOCNO>NCT00431444</DOCNO>
	<brief_summary>This study compare effect Zoledronic acid Raloxifene reduce bone turnover marker postmenopausal woman low bone mineral density 6 month .</brief_summary>
	<brief_title>Effects Zoledronic Acid Raloxifene Bone Turnover Markers Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Females , 45 80 year ( inclusive ) age , consider postmenopausal accord one follow guideline : Cessation menses 18 month woman &lt; 50 year age Cessation menses 12 month woman age 50 year Documented bilateral oophorectomy least 1 year previously Documented T score less equal 1.5 dual energy Xray absorptiometry ( DXA ) scan lumbar spine , total hip femoral neck within 24 month prior screen , clinically indicate treatment bisphosphonates ( BPs ) osteopenia osteoporosis Signed informed consent prior initiation study procedure Prior treatment i.v . bisphosphonates within last 2 year Previous use oral bisphosphonates within past 2 year ( unless use less 8 weeks* ) . *NOTE : If use less 8 week , washout period 6 month . Treatment raloxifene , calcitonin , tibolone hormone replacement therapy . The washout period medication 6 month prior randomization . Any treatment strontium renalate , sodium fluoride parathyroid hormone Use systemic high dose corticosteroid average dose â‰¥ 7.5 mg per day oral prednisone equivalent period three month within previous year Treatment investigational drug within 30 day prior randomization Any woman child bear potential Patients fracture occur within three month prior randomization History hypersensitivity bisphosphonates History nontraumatic uveitis iritis , within 2 year prior study entry . A history invasive malignancy organ system , treat untreated , within past 12 month prior screen ; exclude , basal cell squamous cell carcinoma skin , colonic polyp noninvasive malignancy remove , Ductal Carcinoma insitu ( DCIS ) surgically remove , Carcinoma insitu ( CIS ) uterine cervix surgically remove . Previous major solid organ transplant recipient transplant wait list History hyperparathyroidism , hypoparathyroidism , Osteogenesis imperfecta , Paget 's disease metabolic bone disease osteoporosis Any medical condition would interfere action study drug limit life expectancy le 6 month Any medical psychiatric condition , opinion investigator , would preclude participant adhere protocol complete trial Active dental infection , unhealed dental extraction plan oral surgery within 3 month prior randomization . Calculated creatinine clearance &lt; 30 mL/min Greater 2+ protein urine dipstick without evidence contamination bacteriuria ( may repeat one time , least day apart ) . Serum calcium &gt; 2.75 mmol/L ( 11.0 mg/dL ) &lt; 2.08 mmol/L ( 8.3 mg/dL ) screen AST , ALT serum alkaline phosphatase great twice upper limit normal</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Post-menopausal</keyword>
	<keyword>Bone mineral density</keyword>
</DOC>